E. S. Cohen

Rituximab and Omalizumab for the Treatment of Bullous Pemphigoid: A Systematic Review of the Literature

M. Lapidoth, S. Mazor, E. Hodak, 2018, American Journal of Clinical Dermatology.

Cutaneous presentations of omphalomesenteric duct remnant: a systematic review of the literature.

M. Lapidoth, D. Ben-Amitai, E. Hodak, 2019, Journal of the American Academy of Dermatology.

Tozorakimab (MEDI3506): a dual-pharmacology anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction

B. Kemp, T. Vaughan, Elizabeth England, 2022, bioRxiv.

IL-17A Inhibitor Switching - Efficacy of Ixekizumab Following Secukinumab Failure. A Single-Center Experience.

I. Amitay-Laish, E. Hodak, E. S. Cohen, 2019, Acta dermato-venereologica.